GlassScriptPhysician profile
Bindu A Thomas
NPI 1447202346
$2,083.54
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $118 · 2022: $316 · 2023: $605 · 2024: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $427.23 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $320.07 | 2019-2024 | |
| Amgen INC. | $232.83 | 2019-2024 | Repatha, Otezla |
| Exact Sciences Corporation | $157.24 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $149.28 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $144.80 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $125.59 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $107.82 | 2022-2024 | Qulipta, Synthroid, Ubrelvy |
| Amneal Pharmaceuticals LLC | $66.33 | 2019-2020 | |
| Abbott Laboratories | $66.28 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $46.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.99 | 2019-2024 | |
| Ibsa Pharma INC. | $38.24 | 2019-2020 | |
| Phadia US INC. | $37.54 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $32.77 | 2024 | Voquezna |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.50 | 2019 | |
| Amarin Pharma, INC. | $30.92 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bindu Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.